Cigna (NYSE: CI) today unveiled its new TV Doctors of America campaign to encourage people to improve their health by going for their annual check-up, knowing their biometric numbers for blood pressure, cholesterol, blood sugar and body mass index (BMI), and taking control of their health. Supporting Cigna’s effort are actors Patrick Dempsey, Donald Faison, Neil Patrick Harris and Kate Walsh. All four actors starred as doctors on TV and are striking doctor poses, donning scrubs and using their celebrity influence to shine a spotlight on preventive care and the importance of going to a real doctor for an annual check-up that can help save lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8163851-cigna-americas-tv-doctors-go-know-take-control/
Today, the newly-developed Body Volume Indicator (BVI)™ was revealed as a modern day measure of body composition and weight distribution following a 10-year collaboration with Mayo Clinic experts who led extensive research on fat distribution, the importance of fat assessment and the limitations of the current standard of Body Mass Index (BMI). In conjunction with the development of BVI, BVI America LLC, a subsidiary of 3D measurement pioneer Select Research, announced the launch of the revolutionary BVI Pro tablet application, which will provide an easily accessible and affordable means for the professional community to use the new BVI measurement in everyday clinical use to assess health risks.
The potential benefits of using Body Volume as a new indicator of risks were presented on April 27 by Mayo Clinic researchers, BVI America and the University of Westminster. It draws on 10 years of rigorous research, testing and validation using several potential Body Volume indices. Now BVI, calculated as a ratio between total volume and abdominal volume, can be used as a supplement to the current measurement standard of BMI, which is based solely on height and weight. BVI is considered to be a more precise means of estimating weight distribution and the fat around the organs, which is not visible to the human eye and can lead to serious health conditions, such as diabetes and heart disease. The medical and professional community at large is invited to contribute to the continued development of BVI by downloading and using the BVI Pro tablet application with their patients and clients; anonymous data collected will be analyzed by Mayo Clinic, whose research and validation of BVI will continue.
To view the multimedia release go to:
https://www.multivu.com/players/English/8093051-bvi-america-body-volume-app-health-fitness/
Pivotal Corporation, the Seattle start-up responsible for disrupting the wearable fitness marketplace with its $12 Pivotal Living Band, is pleased to announce pre-order availability for the Pivotal Living Smart Scale, a smarter scale with an even smarter price. Available for $39.95, just a fraction of the cost of most smart scales on the market, the elegant and efficient smart scale integrates seamlessly with the Pivotal Living app to provide a more intelligent way to manage body weight and overall health.
“Our mission has always been to spark a movement toward proactive health and wellness through affordable and powerful, personal health technology,” said David Donovick, CEO for Pivotal Corporation. “We are very proud to introduce a feature-rich smart scale to our family of products and software, and are thrilled to be able to offer it to our members at a pizza-dinner price!”
Using advanced bioimpedance technology, the Pivotal Living Smart Scale accurately measures key body weight and body fat percentage factors, helping people lose weight and stay healthy. Designed to help users identify when they are burning fat, building muscle and losing weight, the sleek smart scale displays weight on the scale’s easy-to-read LCD display screen and, when synced to the Pivotal Living mobile app, sends additional weight and body details. The scale’s four load sensors accurately assess body composition measurements based on weight and height data stored within the app. Working together, the scale and app measure and track.
To view the multimedia release go to:
http://www.multivu.com/players/English/7668051-pivotal-living-bluetooth-smart-scale/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Bad dietary habits and modern sedentary lifestyles have converged to create a worldwide epidemic that is constantly increasing: obesity (BMI > 30).
One billion adults around the world and twenty-two million children under the age of 5 are overweight.
Faced with this problem, LPG wanted to study the effect of LPG® mechano stimulation on fat cells to obtain proven results of the impact of Cellu M6® on localised areas of fat.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/lpg/50526/
